Activities

Work package 4: Phase Ia/Ib evaluation of safety and immunogenicity of InvaplexAR-Detox administered with and without the dmLT adjuvant in The Netherlands and Burkina Faso

Led by Leiden University Medical Center, The Netherlands

The main objectives of this work package are to:

  • To evaluate the safety of three doses of two different dosing formulations of the InvaplexAR-Detox vaccine (2.5 ug and 10 ug) given IM alone or in combination with the dmLT adjuvant (0.1 ug) by the intramuscular route of injection on D0, D21 and D42 in healthy Dutch and Burkinabe adults.

  • To assess the immunogenicity of three doses of two different dosing formulations of the InvaplexAR-Detox vaccine (2.5 ug and 10 ug) given IM alone or in combination with the dmLT adjuvant (0.1 ug) by the intramuscular route of injection on D0, D21 and D42 in healthy Dutch and Burkinabe adults.

Partner